SI
SI
discoversearch

Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
207 50 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
207One analyst thoughts FWIW. ladenburg.bluematrix.com His ranking tipranks.comsemi_infinite -June 30
206O/S closer to 30M so MC of ~480M and EV ~350M assuming over allotment was fullysemi_infinite -June 29
205Look at the bright side. You now have 2 additional choices for betting on CD47 semi_infinite -June 28
204ATM out (to pay for combination therapies that could be kostenlos). Genius CFO/scaram(o)uche-June 28
203FTSV IPO Market cap of ~ 370M and EV of ~270M. Based upon O/S of 23M.semi_infinite -June 28
202FTSV - about the same MC as SURF.semi_infinite -June 21
201latest FTSV S-1.... >> In addition, unless we specifically state otherwisscaram(o)uche-June 20
200Bispecific, CD47 x CD20: finance.yahoo.comMiljenko Zuanic-June 20
199Well, my comment was, of course, silly. Lotsa shares, any category, that donscaram(o)uche-June 11
198Here’s another link to AWM’s filings re TRIL: fintel.io Confusing, but doesn’t BulbaMan-June 11
197Corresponding increase in preferred shares, if all of that data is correct. Wouscaram(o)uche-June 11
196Bulba, How does 11,000,000 drop to 954,000? Something doesn't seem right hBladerunner17-June 11
195Thanks! (eom)scaram(o)uche-June 11
194Also found AWM Trillium info here: fintel.io (Sort alphabetically on Security coBulbaMan-June 11
193>> Hope the Forty Seven IPO catches.... << Needs a reverse split, scaram(o)uche-June 11
192The RSI is strong in the bullish zone and the MACD is trying to cross back up. OAlejandroo Green-June 11
191Just parking a link. Don't know if this is THE preferred, if it's just scaram(o)uche-June 11
190Yeah Rick, I was surprised SURF didn’t get an IPO surge, actually closing down oBulbaMan-June 9
189Market cap $400m..... sec.gov One product in clinical testing, phase I. (I knscaram(o)uche-June 9
188>>> “...for allowing that last round of hiring to be sourced from a VanBulbaMan-June 8
187So Nic finally had the nuts to hire the best person available? Kudos!! Needed dscaram(o)uche-June 7
186Just absolutely disgusting. jay arnold? @jayabacus10h10 hours ago More On closcaram(o)uche-June 6
185Fourty Seven files for IPO. It will have 177M shares outstanding after offeringsemi_infinite -June 1
184Once again, shareholders are paying for the PD1 or PDL1 inhibitor. Or perhaps Dscaram(o)uche-May 29
183Thnx, indeed very good results for small # subjects enrolled. CRs after Rituxan Miljenko Zuanic-May 17
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.